|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings show that pancreatic cancers are insensitive towards TRAIL-mediated apoptosis despite expression of TRAIL and its receptors, suggesting the presence of mediators which inhibit the TRAIL cell-death-inducing pathway in pancreatic cancer cells.
|
11163110 |
2001 |
|
Malignant neoplasm of pancreas
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells.
|
11234897 |
2001 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings give new insight into the resistance mechanisms of pancreatic cancer towards TRAIL-mediated apoptosis.
|
11848467 |
2002 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results suggest that TRAIL gene therapy in combination with gemcitabine might be a useful therapeutic approach for treating metastatic pancreatic cancers.
|
15486557 |
2005 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Geldanamycin, PS-341, and TRAIL triple combination may be a novel therapeutic strategy for pancreatic cancer.
|
15781649 |
2005 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, we observed increased sensitivity of G1-arrested pancreatic cancer cells towards TRAIL-induced apoptosis.
|
17304504 |
2007 |
|
Malignant neoplasm of pancreas
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Thus, our findings for the first time indicate that targeting XIAP represents a promising strategy to enhance the antitumor activity of TRAIL in pancreatic cancer, which has important clinical implications.
|
16832350 |
2007 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
The present study explored the possibility of sensitizing pancreatic cancer to gemcitabine chemotherapy by combining the chemotherapy with the proapoptotic genes Bax and TNF-related apoptosis-inducing ligand (TRAIL).
|
17984977 |
2008 |
|
Malignant neoplasm of pancreas
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TRAIL can stimulate the expression of uPA, IL-8, MMP-7 and MMP-9 in pancreatic cancer cell lines, especially in Colo357wt.
|
18397859 |
2008 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Combined treatment with oncolytic adenovirus-mediated hSSTr2 and TRAIL gene provides the rationale for a clinical trial in pancreatic cancer.
|
19671855 |
2009 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we report that DHA enhances the efficacy of Apo2L/TRAIL for the treatment of pancreatic cancer.
|
22666346 |
2012 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Targeted inhibition of OPG binding to TRAIL may represent a therapeutic approach in the treatment of pancreatic cancer.
|
23219833 |
2013 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, most pancreatic cancers are resistant to TRAIL therapy.
|
23833311 |
2013 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results indicate that MUC5AC inhibits TRAIL‑induced apoptosis in human pancreatic cancer and may serve as an important indicator in diagnosis and prognosis.
|
23292004 |
2013 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Reduction of decoy receptor 3 enhances TRAIL-mediated apoptosis in pancreatic cancer.
|
24204567 |
2013 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
|
25482930 |
2014 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
Restoration of TRAIL-induced apoptosis in resistant human pancreatic cancer cells by a novel FAK inhibitor, PH11.
|
25684663 |
2015 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
TRAIL treatment increased ROS in two TRAIL-sensitive pancreatic cancer cell lines, MiaPaCa-2 and BxPC-3, but ROS were involved in TRAIL-induced apoptosis only in MiaPaCa-2 cells.
|
26000607 |
2015 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill.
|
26138346 |
2015 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
TRAIL-activating therapy has been promising, however, clinical trials have shown resistance and limited responses of pancreatic cancers.
|
26320171 |
2015 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results indicate that Bcl-xL is responsible for TRAIL resistance in human pancreatic cancer cells, and that Bcl-2 family inhibitors could represent promising reagents to sensitize human pancreatic cancers in DR-targeting therapy.
|
26506422 |
2015 |
|
Malignant neoplasm of pancreas
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this study, we demonstrated that survivin downregulation with TRAIL expression greatly enhanced the cytotoxic death of pancreatic cancer cells after gemcitabine treatment.
|
26677013 |
2016 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
The TRAIL mice displayed significantly decreased tumor volumes and an enhanced overall survival in pancreatic cancer.
|
26390425 |
2016 |
|
Malignant neoplasm of pancreas
|
0.400 |
Biomarker
|
disease |
BEFREE |
We found that the novel CTL harboring Lenti/hCD40L/E1AB and Ad5/35-TRAIL inhibited pancreatic cancer cell growth and angiogenesis in vitro and in vivo.
|
27876704 |
2016 |
|
Malignant neoplasm of pancreas
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We observed that TRAIL-resistant pancreatic cancer cells had higher levels of HOTAIR expression, whereas TRAIL-sensitive pancreatic cancer cells had lower HOTAIR levels.
|
28476883 |
2017 |